Abstract: Background: Selecting the first antipsychotic agent after a first episode of psychosis (FEP) is a critical task that may impact on the long-term outcome of the disease. Many randomized clinical trials (RCTs) have compared oral second-generation antipsychotics (SGAs) for the treatment of acute symptoms of schizophrenia spectrum disorders (SSDs), while fewer studies are available for long-term maintenance treatment. As far as we are concerned, this is the first study comparing head-to-head the effectiveness of aripiprazole and risperidone, two of the most widely used SGAs, for the long-term treatment after a first episode of psicosis.
Aim of the study: The aim of this study was to compare the effectiveness of aripiprazole and risperidone for the long-term treatment after a FEP. In shed of previous data from our group obtained along prior stages of the disease (6-week and 12-week follow-up), we hypothesized the non-inferiority of aripiprazole compared to risperidone in terms of effectiveness for the long-term treatment of SSD after a FEP.
Methods: From February 2011 to October 2018, a prospective, open-label, RCT was undertaken in Hospital Universitario Marqués de Valdecilla (Santander, Spain) inpatient and outpatient units. Two hundred-sixty-six FEP, drug-naïve SSD patients were randomly assigned to aripiprazole (n = 136), or risperidone (n = 130) and followed-up for one year. The primary effectiveness measures were all-cause treatment discontinuation rate and mean time until all-cause treatment discontinuation. Analyses were performed following intention-to-treat principles.
Results: A total of 158 patients (59.4%) discontinued treatment by the end of 1-year follow-up. Statistically significant differences (X2 = 13.632; p = 0.000) were observed between all-cause discontinuation (N = 66; 48.5%) favoring the aripiprazole group compared to the risperidone group (N = 92; 70.8%). Nonetheless, Kaplan Mayer survival analysis regarding mean time until all-cause discontinuation did not result in statistically significant differences between treatment groups but again in a trend towards significancy favoring the aripiprazole group (p= 0.0068). Adverse effects were the main reason for discontinuation during the 1-year follow-up period (N = 48; 18%). In this sense, statistically significant differences (X2 = 13.551; p = 0.000) were found between patients under risperidone treatment (N = 13; 9,6%) and patients under aripiprazole treatment (N = 35; 26,9%) regarding the burden of adverse effects as the main reason for discontinuation. We found no significant differences on the remaining reasons considered for discontinuation (insufficient efficacy, non-compliance, and other causes). Nevertheless, there was a trend toward statistical significance regarding noncompliance (5.1% (N = 7) favoring the aripiprazole group over 11.5% (N = 15) the risperidone group).
Conclusions: Patients under aripiprazole treatment were less likely to discontinue antipsychotic treatment due to any reason during the first-year follow-up after a FEP. Adverse effects were the main responsible for differences of discontinuation between both treatment groups, being higher in the risperidone group.
Other publications of the same journal or congress with authors from the University of Cantabria